Stratification of patients with KRAS-mutated advanced non-small cell lung cancer: improving prognostics

References

• Uras IZ, Moll HP, Casanova E. Targeting KRAS mutant non-small-cell lung cancer: past, present and future. Int J Mol Sci. 2020;21(12):4325. doi: 10.3390/ijms21124325
   PubMedGoogle Scholar
• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi: 10.3322/caac.21654
   PubMed Web of Science ®Google Scholar
• McGuigan A, Kelly P, Turkington RC, et al. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018;24(43):4846–4861. doi: 10.3748/wjg.v24.i43.4846
   PubMed Web of Science ®Google Scholar
• Hayama T, Hashiguchi Y, Okamoto K, et al. G12V and G12C mutations in the gene KRAS are associated with a poorer prognosis in primary colorectal cancer. Int J Colorectal Dis. 2019;34(8):1491–1496. doi: 10.1007/s00384-019-03344-9
   PubMed Web of Science ®Google Scholar
• Nagasaka M, Li Y, Sukari A, et al. KRAS G12C game of thrones, which direct KRAS inhibitor will claim the iron throne? Cancer Treat Rev. 2020;84:101974. doi: 10.1016/j.ctrv.2020.101974
   PubMed Web of Science ®Google Scholar
• Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327–3334. doi: 10.1200/JCO.2012.44.2806
   PubMed Web of Science ®Google Scholar
• Wiesweg M, Kasper S, Worm K, et al. Impact of RAS mutation subtype on clinical outcome-a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer. Oncogene. 2019;38(16):2953–2966. doi: 10.1038/s41388-018-0634-0
   PubMed Web of Science ®Google Scholar
• Ostrem JM, Shokat KM. Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. Nat Rev Drug Discov. 2016;15(11):771–785. doi: 10.1038/nrd.2016.139
   PubMed Web of Science ®Google Scholar
• Punekar SR, Velcheti V, Neel BG, et al. The current state of the art and future trends in RAS-targeted cancer therapies. Nat Rev Clin Oncol. 2022;19(10):637–655. doi: 10.1038/s41571-022-00671-9
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–957. doi: 10.1056/NEJMoa0810699
   PubMed Web of Science ®Google Scholar
• Canon J, Rex K, Saiki AY, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575(7781):217–223. doi: 10.1038/s41586-019-1694-1
   PubMed Web of Science ®Google Scholar
• Skoulidis F, Li BT, Dy GK, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384(25):2371–2381. doi: 10.1056/NEJMoa2103695
   PubMed Web of Science ®Google Scholar
• Lanman BA, Allen JR, Allen JG, et al. Discovery of a covalent inhibitor of KRAS(G12C) (AMG 510) for the treatment of solid tumors. J Med Chem. 2020;63(1):52–65. doi: 10.1021/acs.jmedchem.9b01180
   PubMed Web of Science ®Google Scholar
• Hallin J, Engstrom LD, Hargis L, et al. The KRAS(G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-Mutant cancers in mouse models and patients. Cancer Discov. 2020;10(1):54–71. doi: 10.1158/2159-8290.CD-19-1167
   PubMed Web of Science ®Google Scholar
• Skoulidis F, Byers LA, Diao L, et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 2015;5(8):860–877. doi: 10.1158/2159-8290.CD-14-1236
   PubMed Web of Science ®Google Scholar
• Cox AD, Fesik SW, Kimmelman AC, et al. Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov. 2014;13(11):828–851. doi: 10.1038/nrd4389
   PubMed Web of Science ®Google Scholar
• Uprety D, Adjei AK. From undruggable to a druggable cancer target. Cancer Treat Rev. 2020;89:102070. doi: 10.1016/j.ctrv.2020.102070
   PubMed Web of Science ®Google Scholar
• Polo V, Besse B. Maintenance strategies in stage IV non-small-cell lung cancer (NSCLC): in which patients, with which drugs? Ann Oncol. 2014;25(7):1283–1293. doi: 10.1093/annonc/mdt529
   PubMed Web of Science ®Google Scholar
• Skoulidis F, Heymach JV. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer. 2019;19(9):495–509. doi: 10.1038/s41568-019-0179-8
   PubMed Web of Science ®Google Scholar
• Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012;72(10):2457–2467. doi: 10.1158/0008-5472.CAN-11-2612
   PubMed Web of Science ®Google Scholar
• Hobbs GA, Der CJ, Rossman KL. RAS isoforms and mutations in cancer at a glance. J Cell Sci. 2016;129(7):1287–1292. doi: 10.1242/jcs.182873
   PubMed Web of Science ®Google Scholar
• Kamerkar S, LeBleu VS, Sugimoto H, et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature. 2017;546(7659):498–503. doi: 10.1038/nature22341
   PubMed Web of Science ®Google Scholar
• McCormick F. Progress in targeting RAS with small molecule drugs. Biochem J. 2019;476(2):365–374. doi: 10.1042/BCJ20170441
   PubMed Web of Science ®Google Scholar
• Patricelli MP, Janes MR, Li LS, et al. Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. Cancer Discov. 2016;6(3):316–329. doi: 10.1158/2159-8290.CD-15-1105
   PubMed Web of Science ®Google Scholar
• Scheffler M, Ihle MA, Hein R, et al. K-ras mutation Subtypes in NSCLC and associated co-occuring mutations in other oncogenic pathways. J Thorac Oncol. 2019;14(4):606–616. doi: 10.1016/j.jtho.2018.12.013
   PubMed Web of Science ®Google Scholar
• Ostrem JM, Peters U, Sos ML, et al. K-Ras(g12c) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503(7477):548–551. doi: 10.1038/nature12796
   PubMed Web of Science ®Google Scholar
• Reck M, Carbone DP, Garassino M, et al. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann Oncol. 2021;32(9):1101–1110. doi: 10.1016/j.annonc.2021.06.001
   PubMed Web of Science ®Google Scholar
• Kerk SA, Papagiannakopoulos T, Shah YM, et al. Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment. Nat Rev Cancer. 2021;21(8):510–525. doi: 10.1038/s41568-021-00375-9
   PubMed Web of Science ®Google Scholar
• Pushalkar S, Hundeyin M, Daley D, et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov. 2018;8(4):403–416. doi: 10.1158/2159-8290.CD-17-1134
   PubMed Web of Science ®Google Scholar
• Jin C, Lagoudas GK, Zhao C, et al. Commensal microbiota promote lung cancer development via gammadelta T cells. Cell. 2019;176(5):998–1013 e1016. doi: 10.1016/j.cell.2018.12.040
   PubMed Web of Science ®Google Scholar
• Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341(6145):569–573. doi: 10.1126/science.1241165
   PubMed Web of Science ®Google Scholar
• Leinwand J, Miller G. Regulation and modulation of antitumor immunity in pancreatic cancer. Nat Immunol. 2020;21(10):1152–1159. doi: 10.1038/s41590-020-0761-y
   PubMed Web of Science ®Google Scholar
• Tsay JJ, Wu BG, Badri MH, et al. Airway microbiota is associated with upregulation of the PI3K pathway in lung cancer. Am J Respir Crit Care Med. 2018;198(9):1188–1198. doi: 10.1164/rccm.201710-2118OC
   PubMed Web of Science ®Google Scholar
• Segal LN, Clemente JC, Tsay JC, et al. Enrichment of the lung microbiome with oral taxa is associated with lung inflammation of a Th17 phenotype. Nat Microbiol. 2016;1(5):16031. doi: 10.1038/nmicrobiol.2016.31
   PubMed Web of Science ®Google Scholar
• Hu H, Cheng R, Wang Y, et al. Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47. J Clin Invest. 2023;133(2). doi: 10.1172/JCI153470
   Web of Science ®Google Scholar
• Li C, Vides A, Kim D, et al. The G protein signaling regulator RGS3 enhances the GTPase activity of KRAS. Science. 2021;374(6564):197–201. doi: 10.1126/science.abf1730
   PubMed Web of Science ®Google Scholar
• Hennig A, Markwart R, Esparza-Franco MA, et al. Ras activation revisited: role of GEF and GAP systems. Biol Chem. 2015;396(8):831–848. doi: 10.1515/hsz-2014-0257
   PubMed Web of Science ®Google Scholar
• Berta D, Gehrke S, Nyiri K, et al. Mechanism-based redesign of GAP to activate oncogenic Ras. J Am Chem Soc. 2023;145(37):20302–20310. doi: 10.1021/jacs.3c04330
   PubMed Web of Science ®Google Scholar
• Goody RS, Rak A, Alexandrov K. The structural and mechanistic basis for recycling of Rab proteins between membrane compartments. Cell Mol Life Sci. 2005;62(15):1657–1670. doi: 10.1007/s00018-005-4486-8
   PubMed Web of Science ®Google Scholar
• Zhao Y, Xue JY, Lito P. Suppressing nucleotide exchange to inhibit KRAS-Mutant tumors. Cancer Discov. 2021;11(1):17–19. doi: 10.1158/2159-8290.CD-20-1331
   PubMed Web of Science ®Google Scholar
• Cai D, Choi PS, Gelbard M, et al. Identification and Characterization of oncogenic SOS1 mutations in lung adenocarcinoma. Mol Cancer Res. 2019;17(4):1002–1012. doi: 10.1158/1541-7786.MCR-18-0316
   PubMed Web of Science ®Google Scholar
• Erlanson DA, Webster KR. Targeting mutant KRAS. Curr Opin Chem Biol. 2021;62:101–108. doi: 10.1016/j.cbpa.2021.02.010
   PubMed Web of Science ®Google Scholar
• Downward J, Graves JD, Warne PH, et al. Stimulation of p21ras upon T-cell activation. Nature. 1990;346(6286):719–723. doi: 10.1038/346719a0
   PubMed Web of Science ®Google Scholar
• Tulpule A, Guan J, Neel DS, et al. Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules. Cell. 2021;184(10):2649–2664 e2618. doi: 10.1016/j.cell.2021.03.031
   PubMed Web of Science ®Google Scholar
• Hill BT, Perrin D, Kruczynski A. Inhibition of RAS-targeted prenylation: protein farnesyl transferase inhibitors revisited. Crit Rev Oncol Hematol. 2000;33(1):7–23. doi: 10.1016/S1040-8428(99)00053-0
   PubMed Web of Science ®Google Scholar
• Rubio I, Grund S, Song SP, et al. TCR-induced activation of Ras proceeds at the plasma membrane and requires palmitoylation of N-Ras. J Immunol. 2010;185(6):3536–3543. doi: 10.4049/jimmunol.1000334
   PubMed Web of Science ®Google Scholar
• Tang D, Kroemer G, Kang R. Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges. Mol Cancer. 2021;20(1):128. doi: 10.1186/s12943-021-01422-7
   PubMed Web of Science ®Google Scholar
• Koga T, Suda K, Fujino T, et al. KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors, Sotorasib and Adagrasib, and overcoming strategies: insights from in vitro experiments. J Thorac Oncol. 2021;16(8):1321–1332. doi: 10.1016/j.jtho.2021.04.015
   PubMed Web of Science ®Google Scholar
• Awad MM, Liu S, Rybkin II, et al. Acquired resistance to KRAS(G12C) inhibition in cancer. N Engl J Med. 2021;384(25):2382–2393. doi: 10.1056/NEJMoa2105281
   PubMed Web of Science ®Google Scholar
• Hames ML, Chen H, Iams W, et al. Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆. Lung Cancer. 2016;92:29–34. doi: 10.1016/j.lungcan.2015.11.004
   PubMed Web of Science ®Google Scholar
• Mellema WW, Masen-Poos L, Smit EF, et al. Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer. Lung Cancer. 2015;90(2):249–254. doi: 10.1016/j.lungcan.2015.09.012
   PubMed Web of Science ®Google Scholar
• Reuss JE, Anagnostou V, Cottrell TR, et al. Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. J Immunother Cancer. 2020;8(2):e001282. doi: 10.1136/jitc-2020-001282
   PubMed Web of Science ®Google Scholar
• Calles A, Liao X, Sholl LM, et al. Expression of PD-1 and its ligands, PD-L1 and PD-L2, in smokers and never smokers with KRAS-Mutant lung cancer. J Thorac Oncol. 2015;10(12):1726–1735. doi: 10.1097/JTO.0000000000000687
   PubMed Web of Science ®Google Scholar
• Veccia A, Dipasquale M, Kinspergher S, et al. Impact of KRAS mutations on clinical outcomes of patients with advanced non-squamous non-small cell lung cancer receiving anti-PD-1/PD-L1 therapy. Target Oncol. 2023;18(1):129–138. doi: 10.1007/s11523-022-00934-6
   PubMed Web of Science ®Google Scholar
• Frezzetti D, Gallo M, Maiello MR, et al. VEGF as a potential target in lung cancer. Expert Opin Ther Targets. 2017;21(10):959–966. doi: 10.1080/14728222.2017.1371137
   PubMed Web of Science ®Google Scholar
• Brady AK, McNeill JD, Judy B, et al. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy. Oncotarget. 2015;6(30):30287–30294. doi: 10.18632/oncotarget.4711
   PubMedGoogle Scholar
• Passaro A, Leighl N, Blackhall F, et al. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Ann Oncol. 2022;33(5):466–487. doi: 10.1016/j.annonc.2022.02.003
   PubMed Web of Science ®Google Scholar
• Thein KZ, Biter AB, Hong DS. Therapeutics targeting mutant KRAS. Annu Rev Med. 2021;72(1):349–364. doi: 10.1146/annurev-med-080819-033145
   PubMedGoogle Scholar
• Pan LN, Ma YF, Li Z, et al. KRAS G12V mutation upregulates PD-L1 expression via TGF-beta/EMT signaling pathway in human non-small-cell lung cancer. Cell Biol Int. 2021;45(4):795–803. doi: 10.1002/cbin.11524
   PubMed Web of Science ®Google Scholar
• Salem ME, El-Refai SM, Sha W, et al. Landscape of KRAS G12C , associated genomic alterations, and interrelation with immuno-Oncology biomarkers in KRAS -mutated cancers. JCO Precis Oncol. 2022;6(6):e2100245. doi: 10.1200/PO.21.00245
   PubMedGoogle Scholar
• Toki MI, Mani N, Smithy JW, et al. Immune marker profiling and programmed death ligand 1 expression across NSCLC mutations. J Thorac Oncol. 2018;13(12):1884–1896. doi: 10.1016/j.jtho.2018.09.012
   PubMed Web of Science ®Google Scholar
• Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019;30(8):1321–1328. doi: 10.1093/annonc/mdz167
   PubMed Web of Science ®Google Scholar
• Mok TSK, Lopes G, Cho BC, et al. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC. Ann Oncol. 2023;34(4):377–388. doi: 10.1016/j.annonc.2023.01.011
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639. doi: 10.1056/NEJMoa1507643
   PubMed Web of Science ®Google Scholar
• Landre T, Justeau G, Assie JB, et al. Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: a meta-analysis of randomized-controlled trials. Cancer Immunol Immunother. 2022;71(3):719–726. doi: 10.1007/s00262-021-03031-1
   PubMed Web of Science ®Google Scholar
• Ryan MB, Corcoran RB. Therapeutic strategies to target RAS-mutant cancers. Nat Rev Clin Oncol. 2018;15(11):709–720. doi: 10.1038/s41571-018-0105-0
   PubMed Web of Science ®Google Scholar
• Hunter JC, Manandhar A, Carrasco MA, et al. Biochemical and structural analysis of common cancer-associated KRAS mutations. Mol Cancer Res. 2015;13(9):1325–1335. doi: 10.1158/1541-7786.MCR-15-0203
   PubMed Web of Science ®Google Scholar
• Biernacka A, Tsongalis PD, Peterson JD, et al. The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma. Cancer Genet. 2016;209(5):195–198. doi: 10.1016/j.cancergen.2016.03.001
   PubMed Web of Science ®Google Scholar
• Hong DS, Fakih MG, Strickler JH, et al. KRAS(G12C) inhibition with Sotorasib in advanced solid tumors. N Engl J Med. 2020;383(13):1207–1217. doi: 10.1056/NEJMoa1917239
   PubMed Web of Science ®Google Scholar
• de Langen AJ, Johnson ML, Mazieres J, et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial. Lancet. 2023;401(10378):733–746. doi: 10.1016/S0140-6736(23)00221-0
   PubMed Web of Science ®Google Scholar
• Ou SI, Janne PA, Leal TA, et al. First-in-human phase I/IB dose-finding study of Adagrasib (MRTX849) in patients with advanced KRAS(G12C) solid tumors (KRYSTAL-1). J Clin Oncol. 2022;40(23):2530–2538. doi: 10.1200/JCO.21.02752
   PubMed Web of Science ®Google Scholar
• Janne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C) mutation. N Engl J Med. 2022;387(2):120–131. doi: 10.1056/NEJMoa2204619
   PubMed Web of Science ®Google Scholar
• Janes MR, Zhang J, Li LS, et al. Targeting KRAS mutant cancers with a Covalent G12C-Specific inhibitor. Cell. 2018;172(3):578–589 e517. doi: 10.1016/j.cell.2018.01.006
   PubMed Web of Science ®Google Scholar
• Zeng M, Xiong Y, Safaee N, et al. Exploring targeted degradation strategy for oncogenic KRAS(G12C). Cell Chem Biol. 2020;27(1):19–31 e16. doi: 10.1016/j.chembiol.2019.12.006
   PubMed Web of Science ®Google Scholar
• Bond MJ, Chu L, Nalawansha DA, et al. Targeted degradation of oncogenic KRAS(G12C) by VHL-Recruiting PROTACs. ACS Cent Sci. 2020;6(8):1367–1375. doi: 10.1021/acscentsci.0c00411
   PubMed Web of Science ®Google Scholar
• Papadimitrakopoulou V, Lee JJ, Wistuba II, et al. The BATTLE-2 study: a biomarker-integrated targeted therapy study in Previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2016;34(30):3638–3647. doi: 10.1200/JCO.2015.66.0084
   PubMed Web of Science ®Google Scholar
• Sacher A, LoRusso P, Patel MR, et al. Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation. N Engl J Med. 2023;389(8):710–721. doi: 10.1056/NEJMoa2303810
   PubMed Web of Science ®Google Scholar
• Li Z, Song Z, Zhao Y, et al. D-1553 (Garsorasib), a potent and selective inhibitor of KRAS(G12C) in patients with NSCLC: phase 1 study results. J Thorac Oncol. 2023;18(7):940–951. doi: 10.1016/j.jtho.2023.03.015
   PubMed Web of Science ®Google Scholar
• Berndt N, Hamilton AD, Sebti SM. Targeting protein prenylation for cancer therapy. Nat Rev Cancer. 2011;11(11):775–791. doi: 10.1038/nrc3151
   PubMed Web of Science ®Google Scholar
• Yam C, Murthy RK, Valero V, et al. A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. Invest New Drugs. 2018;36(2):299–306. doi: 10.1007/s10637-018-0564-2
   PubMed Web of Science ®Google Scholar
• Fell JB, Fischer JP, Baer BR, et al. Identification of the clinical development Candidate MRTX849, a covalent KRAS(G12C) inhibitor for the treatment of cancer. J Med Chem. 2020;63(13):6679–6693. doi: 10.1021/acs.jmedchem.9b02052
   PubMed Web of Science ®Google Scholar
• Wood K, Hensing T, Malik R, et al. Prognostic and predictive value in KRAS in non-small-cell lung cancer: a review. JAMA Oncol. 2016;2(6):805–812. doi: 10.1001/jamaoncol.2016.0405
   PubMed Web of Science ®Google Scholar
• Nakajima EC, Drezner N, Li X, et al. FDA approval Summary: sotorasib for KRAS G12C-Mutated metastatic NSCLC. Clin Cancer Res. 2022;28(8):1482–1486. doi: 10.1158/1078-0432.CCR-21-3074
   PubMed Web of Science ®Google Scholar
• Zhu C, Guan X, Zhang X, et al. Targeting KRAS mutant cancers: from druggable therapy to drug resistance. Mol Cancer. 2022;21(1):159. doi: 10.1186/s12943-022-01629-2
   PubMed Web of Science ®Google Scholar
• Mainardi S, Mulero-Sanchez A, Prahallad A, et al. SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo. Nat Med. 2018;24(7):961–967. doi: 10.1038/s41591-018-0023-9
   PubMed Web of Science ®Google Scholar
• Suzuki S, Yonesaka K, Teramura T, et al. KRAS inhibitor resistance in MET-Amplified KRAS (G12C) non-small cell lung cancer induced by RAS- and non-RAS-Mediated cell signaling mechanisms. Clin Cancer Res. 2021;27(20):5697–5707. doi: 10.1158/1078-0432.CCR-21-0856
   PubMed Web of Science ®Google Scholar
• Bannoura SF, Uddin MH, Nagasaka M, et al. Targeting KRAS in pancreatic cancer: new drugs on the horizon. Cancer Metastasis Rev. 2021;40(3):819–835. doi: 10.1007/s10555-021-09990-2
   PubMed Web of Science ®Google Scholar
• Negri F, Bottarelli L, De’angelis GL, et al. KRAS: a druggable target in colon cancer patients. Int J Mol Sci. 2022;23(8):4120. doi: 10.3390/ijms23084120
   PubMed Web of Science ®Google Scholar